Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IG-8801 in chronic low back pain
2015-004269-96Phase 2Active
- Sponsor
- Gador S.A.
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olpadronate in chronic low back pain (CLBP) (3 arms), sponsored by Gador S.A. Primary endpoint: Change in daily average pain intensity from baseline to Week 24. Started Feb 2016; status: active.
02
Drugs
olpadronate
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on 2015-004269-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004269-96.